Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Palvella Therapeutics
125 Strafford Avenue, Suite #360
Wayne, PA 19087
Phone: 484-253-1460
https://palvellatx.com/

Founded and led by rare disease veterans, Palvella Therapeutics is a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments. Palvella's development model involves partnering with patient advocacy organizations and their patient registries to design fit-for-purpose, accelerated clinical development programs aimed at expediting the introduction of targeted therapies to patients who currently lack any approved treatment options. Palvella's lead program, PTX-022 (QTORIN™ 3.9% rapamycin anhydrous gel), is in a Phase 2/3 pivotal study for pachyonychia congenita (PC), a rare, chronically debilitating and lifelong genetic disease estimated to affect more than 9,000 individuals in the U.S.

Key Contact
Name
Wes Kaupinen
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
05/30/20 $45,000,000 Series C Adams Street Partners
Agent Capital
BioAdvance
BVF Partners
CAM Capital
Ligand Pharmaceuticals
Nolan Capital
Opaleye Management
Samsara BioCapital
undisclosed